In this recent opinion piece in Life Science Daily News, Conscience CEO Peng Fu and Communications Lead Estrid Jakobsen argue that AI drug discovery is advancing faster than our ability to evaluate it — and that without rigorous, shared benchmarking standards, the field risks mistaking hype for genuine progress. Drawing on examples from initiatives like CASP and the DREAM Challenges, they make the case that community-driven evaluation frameworks have historically been catalysts for real scientific breakthroughs, and that drug discovery AI urgently needs the same. The piece introduces Conscience’s Benchmarking, Evaluation, and Assessment Consortium (BEACON) as a step toward building that shared infrastructure for the biomedical AI community.
